1-6 of 6
Authors: Richard Gilson
Journal Article
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial)
Journal of Antimicrobial Chemotherapy, Volume 72, Issue 6, June 2017, Pages 1760–1768, https://doi.org/10.1093/jac/dkx062
Published: 20 March 2017
Journal Article
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study
Journal of Antimicrobial Chemotherapy, Volume 68, Issue 10, October 2013, Pages 2339–2343, https://doi.org/10.1093/jac/dkt199
Published: 27 May 2013
Journal Article
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring Get access
Journal of Antimicrobial Chemotherapy, Volume 68, Issue 6, June 2013, Pages 1354–1359, https://doi.org/10.1093/jac/dkt029
Published: 23 February 2013
Journal Article
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor Get access
Journal of Antimicrobial Chemotherapy, Volume 67, Issue 4, April 2012, Pages 995–1000, https://doi.org/10.1093/jac/dkr569
Published: 17 January 2012
Journal Article
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study Get access
Journal of Antimicrobial Chemotherapy, Volume 66, Issue 8, August 2011, Pages 1886–1896, https://doi.org/10.1093/jac/dkr171
Published: 30 May 2011
Journal Article
Factors influencing lopinavir and atazanavir plasma concentration Get access
Journal of Antimicrobial Chemotherapy, Volume 65, Issue 1, January 2010, Pages 129–137, https://doi.org/10.1093/jac/dkp408
Published: 06 November 2009
